This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Myos Rens Technology's Median PS Value or its related term are showing as below:
MYOS's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.8 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Myos Rens Technology Median PS Value Historical Data
The historical data trend for Myos Rens Technology's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Myos Rens Technology's Median PS Value
For the Drug Manufacturers - Specialty & Generic subindustry, Myos Rens Technology's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myos Rens Technology's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Myos Rens Technology's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Myos Rens Technology's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Myos Rens Technology's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myos Rens Technology (NAS:MYOS) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Myos Rens Technology's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
12.12
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myos Rens Technology Median PS Value Related Terms
Thank you for viewing the detailed overview of Myos Rens Technology's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Myos Rens Technology (Myos Rens Technology) Business Description
Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYOS has been successfully added to your 